PPAP (Phenylpropylaminopentane)

PPAP (Phenylpropylaminopentane)

PPAP (Phenylpropylaminopentane)

PPAP (Phenylpropylaminopentane)

PPAP (Phenylpropylaminopentane / 1-phenyl-2-propylaminopentane) is a phenylalkylamine examined in catecholamine uptake and stimulation-coupled release assays. Free base C14H23N, 205.34 g/mol. Supplied as a 30 mL amber glass bottle with a 1 mL precision dropper at 50 mg/mL. R-(−) and racemic identifiers differ; salt form is separate.

Original price was: $69.00.Current price is: $48.30.

Out of stock

Want to be notified when this product is back in stock?

What is PPAP (Phenylpropylaminopentane)?

PPAP (1-phenyl-2-propylaminopentane, also named 1-phenyl-N-propylpentan-2-amine) is a small phenylalkylamine. Its secondary amine carries a propyl group, and the carbon beside the nitrogen is a stereocenter. It is not a peptide and not an amino acid. The free base has formula C14H23N and molecular weight 205.34 g/mol (PubChem CID 10262369; PubChem CID 51529346).

The name needs one careful distinction. The stereochemistry-unspecified PubChem entry, CID 10262369, includes the racemic identity and CAS 119485-94-8. The R-(−) entry is CID 51529346, CAS 784118-64-5. Both have the same elemental formula and molecular weight; they do not carry the same stereochemical information. Neither free-base record should be silently substituted for a hydrochloride salt record.

This listing is prepared as a 30 mL amber glass bottle with a 1 mL precision dropper at 50 mg/mL. The bottle and concentration describe the supplied presentation; they do not change the free-base molecular identity recorded above.

Published work used PPAP to examine catecholamine uptake and, in later work, the coupling between an arriving electrical signal and transmitter release. The 1992 report described uptake inhibition without direct catecholamine-releasing activity. The 1996 report separated the catecholaminergic activity enhancer effect from uptake inhibition and monoamine oxidase inhibition. These are different experimental questions, not interchangeable labels for one measured endpoint (Knoll et al., 1992, PubMed 1356324; Knoll et al., 1996, PubMed 8602114).

At Modern Aminos Home, the closest structural comparison is BPAP Product Page. The useful starting point is the aromatic ring: phenyl in PPAP, benzofuran-2-yl in BPAP. A short name is a helpful label, but the full chemical identity is the better guide when comparing the two.

Chemical and Molecular Data for PPAP (Phenylpropylaminopentane)

Compound Name PPAP (Phenylpropylaminopentane)
Research Category Phenylalkylamine; secondary amine; catecholaminergic release-coupling research
Synonyms / Alt Names 1-phenyl-2-propylaminopentane; 1-phenyl-N-propylpentan-2-amine; N,α-dipropylbenzeneethanamine
CAS Number 119485-94-8 (racemic reference; PubChem CID 10262369); 784118-64-5 (R-(−) reference; PubChem CID 51529346)
PubChem CID PubChem CID 10262369 (stereochemistry unspecified / racemic entry); PubChem CID 51529346 (R-enantiomer)
UNII M94L7YXE88 (racemic); UZ3Q3C2Z57 (R-enantiomer)
Chemical Formula C14H23N (free base)
Molecular Weight 205.34 g/mol (free base; both stereochemical reference entries)
Format & Packaging 30 mL amber glass bottle with a 1 mL precision dropper
Concentration 50 mg/mL
Exact Mass 205.183049738 Da (PubChem computed monoisotopic mass)
Stereochemistry One stereocenter at carbon 2; R-(−) and racemic records are distinct
IUPAC Name 1-phenyl-N-propylpentan-2-amine (unspecified); (2R)-1-phenyl-N-propylpentan-2-amine (R form)
InChIKey PBENSVGEGPJNFJ-UHFFFAOYSA-N (unspecified); PBENSVGEGPJNFJ-CQSZACIVSA-N (R form)
SMILES Code CCCC(CC1=CC=CC=C1)NCCC (connectivity only; does not specify R or S)

The entries above describe the two PubChem free-base references, not a lot-specific certificate. R and racemic identity are kept separate so that one record is not mistaken for the other. The connectivity SMILES deliberately leaves stereochemistry unspecified; the R-specific InChIKey belongs only to the R record (PubChem CID 10262369; PubChem CID 51529346).

Molecular weight and exact mass answer different chemistry questions. Molecular weight uses the conventional atomic-weight composition; exact mass refers to a specified isotopic composition. Their different numbers are not evidence of different compounds. Salt composition is a separate matter: adding an acid component changes the formula unit, while changing an enantiomer does not change the elemental formula.

What are the Mechanisms of Action?

The biochemical questions in the PPAP literature can be separated into four connected parts:

  • Catecholamine uptake: The founding report measured uptake of labeled PPAP and inhibition of labeled noradrenaline and dopamine uptake. It described interference with uptake while distinguishing PPAP from compounds that directly release catecholamines. Uptake is the movement of transmitter through a transport system, not the same measurement as signal-triggered release (Knoll et al., 1992, PubMed 1356324).
  • Stimulation-coupled release: The 1996 report concluded that (−)-PPAP acts primarily on action potential–transmitter release coupling in the catecholaminergic assay system. The term catecholaminergic activity enhancer describes this functional relationship between stimulation and measured transmitter output (Knoll et al., 1996, PubMed 8602114).
  • Separation from MAO inhibition: The same report described PPAP as devoid of monoamine oxidase inhibitory potency and found the enhancer effect unrelated to MAO inhibition. PPAP should therefore not be treated as another name for the MAO-B activity of its historical comparator, deprenyl (Knoll et al., 1996, PubMed 8602114).
  • Stereochemical and scaffold comparisons: The 1996 study compared (−)-PPAP with (+)-PPAP in an inward calcium-current assay and found a difference in activity. The later BPAP program changed the aromatic ring. Together, these comparisons make configuration and ring identity important labels on the assay record; they do not establish a universal potency ranking (Knoll et al., 1996, PubMed 8602114; Knoll et al., 1999, PubMed 10588928).
Uptake endpoint PPAP uptake and inhibition of labeled noradrenaline and dopamine uptake; founding report (Knoll et al., 1992, PubMed 1356324)
Release-coupling endpoint Enhancer effect distinguished from uptake inhibition and direct release (Knoll et al., 1996, PubMed 8602114)
MAO contribution Enhancer effect described as unrelated to MAO inhibition (Knoll et al., 1996, PubMed 8602114)
Receptor affinity No PPAP receptor Ki or binding-site assignment is provided by these cited abstracts

An uptake assay, a release assay and an enzyme assay each observe a different control point. Reading their endpoints separately avoids a common mistake: taking a result from one format and making it a general explanation for every other format. The term enhancer is a description of the studied release response, not a substitute for an identified receptor or an affinity measurement.

What Does Published Research Show for PPAP?

The PPAP literature provides a sequence of chemistry and mechanism questions rather than a single, settled molecular-target story:

  • Founding pharmacology, 1992: PPAP was selected from a deprenyl-derived structure-activity program. Labeled uptake experiments were part of the work, and direct catecholamine release was distinguished from interference with uptake. Those findings support a discussion of transporter-related endpoints without supplying a general receptor-binding claim (Knoll et al., 1992, PubMed 1356324).
  • Release-coupling analysis, 1996: The study compared stimulation-related catecholamine release and concluded that the enhancer effect was unrelated to MAO activity, presynaptic catecholamine receptor inhibition, uptake inhibition or direct release. Its conclusion is about the enhancer effect under the examined conditions, not a denial that uptake effects had been measured elsewhere (Knoll et al., 1996, PubMed 8602114).
  • Aromatic-ring comparison, 1999: The BPAP report explicitly identifies PPAP as a phenyl-containing predecessor and describes changing the aromatic ring to develop the benzofuran compound. Numerical findings for BPAP in that report remain BPAP findings; they are not PPAP measurements (Knoll et al., 1999, PubMed 10588928).
  • Chemical directory verification: PubChem separates the unspecified/racemic reference from the R-enantiomer while retaining the same free-base formula, molecular weight and connectivity. Configuration is encoded in the R-specific identifier rather than in the connectivity-only SMILES (PubChem CID 10262369; PubChem CID 51529346).
  • Analytical quality: Reference identity and sample testing are different layers of evidence. The public introduction to HPLC testing explains the chromatographic side of that distinction. No numerical PPAP purity result or lot-specific testing claim is inferred from a database entry.

These papers are easiest to read in order. Start with what was measured, then ask what inference the authors drew from it. A later interpretation can refine an earlier description without making every earlier experimental observation disappear. That is especially important here because the terms uptake inhibitor and activity enhancer refer to different parts of the experimental design.

How does PPAP compare to other compounds?

For the related reference listings at Modern Aminos Home, chemistry provides a clear first comparison. The following distinctions come from the cited PPAP and BPAP reports rather than from an assumed shared mechanism.

PPAP, unspecified / racemic reference Phenyl secondary amine; PubChem CID 10262369. A record without specified configuration does not identify an R-only sample (PubChem CID 10262369).
R-(−)-PPAP Same free-base connectivity and formula, with R configuration specified; PubChem CID 51529346. The 1996 mechanistic report names (−)-PPAP (PubChem CID 51529346; Knoll et al., 1996, PubMed 8602114).
BPAP Benzofuran-2-yl replaces the phenyl group in the related structure-activity program. It is a different molecule with its own release-assay results (Knoll et al., 1999, PubMed 10588928).
Deprenyl Historical comparator with MAO inhibitory potency; the cited PPAP work separates enhancer activity from MAO inhibition (Knoll et al., 1996, PubMed 8602114).

The practical reading rule is simple: match the molecule before comparing the measurement. A value reported for BPAP does not become a PPAP value because the names are similar. Likewise, a result attached to (−)-PPAP does not identify an unspecified sample as that enantiomer. The public Is BPAP a Peptide? Benzofuranylpropylaminopentane Explained provides the benzofuran side of this comparison.

Frequently Asked Questions (FAQs)

1. Is PPAP a peptide or an amino acid?

No. PPAP is a small phenylalkylamine with a secondary amine. Its structure has neither a peptide backbone nor a carboxylic acid group, and its free-base formula is C14H23N.

2. What does the name phenylpropylaminopentane describe?

It describes the phenyl group and propyl-substituted amine on a pentane chain. The name 1-phenyl-2-propylaminopentane refers to the same connectivity that PubChem names 1-phenyl-N-propylpentan-2-amine.

3. Which CAS number belongs to PPAP?

CAS 119485-94-8 identifies the racemic reference associated with PubChem CID 10262369. CAS 784118-64-5 identifies the R-(−) reference associated with CID 51529346. These identifiers distinguish chemical forms rather than establish the composition of a particular lot.

4. What is the molecular weight of PPAP?

PubChem lists 205.34 g/mol for the C14H23N free base in both the stereochemistry-unspecified and R-enantiomer records. A hydrochloride salt includes an additional acid component and must not be assigned the free-base formula without qualification.

5. What mechanism did the PPAP studies examine?

The 1996 study examined action potential–transmitter release coupling and distinguished the enhancer effect from monoamine oxidase inhibition, uptake inhibition and direct catecholamine release. This is a functional assay description, not a receptor binding constant (Knoll et al., 1996, PubMed 8602114).

6. Is PPAP the same compound as BPAP?

No. PPAP has a phenyl ring, while BPAP has a benzofuran-2-yl ring. The 1999 structure-activity program describes the aromatic-ring change that led from PPAP to BPAP (Knoll et al., 1999, PubMed 10588928). The BPAP Product Page covers the separate benzofuran compound.

7. Does R-(−)-PPAP mean the same thing as racemic PPAP?

No. R identifies one absolute configuration, while (−) describes the direction of optical rotation for that form. Racemic PPAP contains both enantiomers, and a connectivity-only structure does not by itself establish an enantiomeric ratio.

8. Is PPAP HCl identical to PPAP free base?

The parent amine is related, but the chemical forms are not identical. HCl denotes a hydrochloride salt, which adds a counter-ion and changes the full formula and formula weight. Salt identity and stereochemical identity are separate checks.

9. Does the PubChem structure establish the identity of a lot?

No. A database structure records a reference identity. It does not establish the salt form, stereochemical composition, identity or chromatographic purity of an individual lot; those are separate analytical questions.

10. Where is the chemistry and mechanism explainer for PPAP?

The companion article, What Is PPAP? Phenylpropylaminopentane Explained, walks through the two chemical records and the distinction between uptake and stimulation-coupled release. It also explains why BPAP findings should not be assigned to PPAP.

11. What format and concentration is this PPAP listing?

This PPAP listing is a 30 mL amber glass bottle with a 1 mL precision dropper at 50 mg/mL. Format and concentration describe the supplied presentation and are separate from free-base formula, stereochemical identity and salt form.

DISCLAIMER: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). No products are approved for oral, sublingual, nor in vivo use. These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.

0